Intravitreal Ziv-Aflibercept for Diabetic Macular Edema : 48-Week Outcomes
Copyright 2018, SLACK Incorporated.
| Publié dans: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 49(2018), 4 vom: 01. Apr., Seite 245-250 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2018
|
| Accès à la collection: | Ophthalmic surgery, lasers & imaging retina |
| Sujets: | Clinical Trial Journal Article Research Support, Non-U.S. Gov't Recombinant Fusion Proteins aflibercept 15C2VL427D Receptors, Vascular Endothelial Growth Factor EC 2.7.10.1 |
| Résumé: | Copyright 2018, SLACK Incorporated. BACKGROUND AND OBJECTIVE: To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME) PATIENTS AND METHODS: Seven consecutive patients with DME were enrolled and submitted to 12 consecutive IVI-ZA with a 4-week interval. The safety parameters included changes in full-field electroretinogram (ERG) and systemic or ocular complications, and the efficacy parameters were the mean change from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) RESULTS: No significant differences were found in any ERG component after IVI-ZA, and no systemic or ocular complication was observed. The improvement of BCVA was most significant after the first IVI-ZA and remained until week 48 (P < .05). The CRT significantly decreased during the course of 48 weeks CONCLUSION: The 48-week results are consistent with our previous 24-week findings, supporting IVI-ZA as a safe, efficient, and well-tolerated therapy for patients with DME. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:245-250.] |
|---|---|
| Description: | Date Completed 11.03.2019 Date Revised 11.03.2019 published: Print Citation Status MEDLINE |
| ISSN: | 2325-8179 |
| DOI: | 10.3928/23258160-20180329-06 |